Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic Lupus Erythematosus Vasculitis: A Current Therapeutic Overview.

Elias Toubi1, Aharon Kessel, Ellen Bamberger

  • 1Division of Clinical Immunology, Bnai-Zion Medical Center, P.O. Box 4940, Haifa 31048, Israel. elias.toubi@b-zion.org.il

Current Treatment Options in Cardiovascular Medicine
|April 7, 2004
PubMed
Summary

Early treatment of systemic lupus erythematosus (SLE) vasculitis improves prognosis. Aggressive therapies are needed for severe or visceral SLE vasculitis, with novel autoimmune treatments showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Variation in Post-Dose Supervision and Activity Restriction During Maintenance Cow's Milk Oral Immunotherapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

The World Allergy Organization journal·2026
Same author

[Primary Prevention of Food Allergies - Is It Feasible?]

Harefuah·2026
Same author

The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.

The World Allergy Organization journal·2026
Same author

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

[Eosinophilic Gastrointestinal Diseases: Diving beyond the Tip of the Iceberg].

Harefuah·2026

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Systemic lupus erythematosus (SLE) vasculitis significantly impacts patient prognosis.
  • Cutaneous SLE vasculitis is common and treatable with antimalarials, but relapse can occur upon discontinuation.
  • Visceral SLE vasculitis is rare but indicates a severe disease state requiring aggressive management.

Purpose of the Study:

  • To review the prognostic value and treatment strategies for SLE vasculitis.
  • To highlight the differences in management between cutaneous and visceral SLE vasculitis.
  • To explore emerging therapies for SLE vasculitis.

Main Methods:

  • Literature review of SLE vasculitis management.
  • Analysis of treatment outcomes based on vasculitis type (cutaneous vs. visceral).

Related Experiment Videos

  • Discussion of current and investigational therapeutic approaches.

    • Main Results:

    • Timely treatment of SLE vasculitis is crucial for better outcomes.
    • Antimalarials are effective for cutaneous SLE vasculitis, but vigilance is needed to prevent flares.
    • Severe or visceral SLE vasculitis necessitates combination therapies including high-dose steroids, cytotoxic drugs, plasmapheresis, and IVIg.

    Conclusions:

    • Prognosis of SLE vasculitis is closely linked to treatment timing and aggressiveness.
    • Novel immunomodulatory therapies targeting cytokines, TLRs, chemokines, FcR, and B-cells offer future treatment avenues for SLE vasculitis.